Effect of Estriol on Bone Loss in Postmenopausal Japanese Women: A Multicenter Prospective Open Study
Autor: | Toshihiko Kinoshita, Tsuguo Uemura, Takeshi Aso, Takumi Kurabayashi, Kenichi Tanaka, Yoshito Ibuki, Kazuhiro Shirasu, Masao Fukunaga, Koji Kusuhara, Takao Koyama, Toshiyuki Ikeda, Junzo Kato, Susumu Tsukikawa, Yusuke Minagawa, Kazuhiko Ochiai, Akira Sato, Hiroaki Ohta, Shiro Nozawa, Hiroshi Minaguchi, Hideki Mizunuma |
---|---|
Rok vydání: | 1996 |
Předmět: |
Bone mineral
medicine.medical_specialty Bone density Estriol business.industry Osteoporosis Urology Obstetrics and Gynecology Middle Aged medicine.disease Bone remodeling Menopause Endocrinology Bone Density Internal medicine medicine Humans Female Prospective Studies Prospective cohort study Climacteric business Osteoporosis Postmenopausal |
Zdroj: | Journal of Obstetrics and Gynaecology Research. 22:259-265 |
ISSN: | 1341-8076 |
DOI: | 10.1111/j.1447-0756.1996.tb00976.x |
Popis: | Objectives: To assess the effects of oral estriol on the bone mineral density (BMD) and bone metabolism in postmenopausal women. Methods: Seventy-five natural postmenopausal women with a BMD of more than 10% below the peak bone density were treated for 50 weeks with 2 mg/day estriol (E3) cyclically and 0.8 g/day of calcium lactate continuously. BMDs at L2-L4 were measured by dual energy X-ray absorptiometry (DXA). Results: The BMD increased 1.79% (p < 0.01 vs. pretreatment) after 50 weeks, accompanied with decrease of biochemical markers of bone turnover. With regard to climacteric symptoms, Kupperman's menopausal index improved (p < 0.01 vs. pre-treatment) after 5 weeks of treatment. As to the incidence of adverse events genital bleeding was observed in only 8.0% of the subjects. Endometrial histology and cytology showed neither abnormalities nor hyperplasia during and after the treatment. Conclusions: Estriol prevented postmenopausal bone loss and improved climacteric symptoms effectively with low incidence of genital bleeding. |
Databáze: | OpenAIRE |
Externí odkaz: |